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ABSTRACT Uropathogenic Escherichia coli (UPEC) is the primary cause of community-acquired urinary tract infections (UTIs).
UPEC bind the bladder using type 1 pili, encoded by the fim operon in nearly all E. coli. Assembled type 1 pili terminate in the
FimH adhesin, which specifically binds to mannosylated glycoproteins on the bladder epithelium. Expression of type 1 pili is
regulated in part by phase-variable inversion of the genomic element containing the fimS promoter, resulting in phase ON (ex-
pressing) and OFF (nonexpressing) orientations. Type 1 pili are essential for virulence in murine models of UTI; however, stud-
ies of urine samples from human UTI patients demonstrate variable expression of type 1 pili. We provide insight into this para-
dox by showing that human urine specifically inhibits both expression and function of type 1 pili. Growth in urine induces the
fimS phase OFF orientation, preventing fim expression. Urine also contains inhibitors of FimH function, and this inhibition
leads to a further bias in fimS orientation toward the phase OFF state. The dual effect of urine on fimS regulation and FimH
binding presents a potential barrier to type 1 pilus-mediated colonization and invasion of the bladder epithelium. However,
FimH-mediated attachment to human bladder cells during growth in urine reverses these effects such that fim expression re-
mains ON and/or turns ON. Interestingly, FimH inhibitors called mannosides also induce the fimS phase OFF orientation. Thus,
the transduction of FimH protein attachment or inhibition into epigenetic regulation of type 1 pilus expression has important
implications for the development of therapeutics targeting FimH function.
IMPORTANCE Urinary tract infections (UTIs) are extremely common infections, frequently caused by uropathogenic Escherichia
coli (UPEC), that are treated with antibiotics but often recur. Therefore, UTI treatment both is complicated by and contributes
to bacterial antibiotic resistance. Thus, it is important to understand UTI pathogenesis to devise novel strategies and targets for
prevention and treatment. Based on evidence from disease epidemiology andmouse models of infection, UPEC relies heavily on
type 1 pili to attach to and invade the bladder epithelium during initial stages of UTI. Here, we demonstrate that the negative
effect of planktonic growth in human urine on both the function and expression of type 1 pili is overcome by attachment to blad-
der epithelial cells, representing a strategy to subvert this alternative innate defense mechanism. Furthermore, this dually inhibi-
tory action of urine is a mechanism shared with recently developed anti-type 1 pilus molecules, highlighting the idea that further
development of antivirulence strategies targeting pili may be particularly effective for UPEC.
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Uropathogenic Escherichia coli (UPEC) is the primary cause ofcommunity-acquired urinary tract infections (UTIs), which
are extremely common and often recurrent (1). UPEC strains are
thought to be distinct from other classes of E. coli, particularly
commensal and intestinal pathogenic strains, due to their carriage
of several virulence factors enabling specific host-pathogen inter-
actions in the urinary tract. For example, UPEC strains typically
encode a multitude of pili assembled by the chaperone-usher
pathway, termedCUPpili, which are important in virulence. CUP
pili terminate in specialized adhesins that recognize specific recep-
tors with stereochemical specificity. If targeted to host receptors,
such pilus adhesin interactions can determine both tissue tropism
and the course of disease. For example, type 1 pili, encoded by the
fim operon, terminate in the FimH adhesin, which binds specifi-
cally to mannosylated uroplakins lining the superficial bladder
epithelium and mannosylated 3,1 integrins expressed on un-
derlying layers of epithelial cells (2–4). FimH-mediated adhesion
enables UPEC colonization and invasion of bladder epithelial
cells. However, UPEC can be expelled from host cells in a Tlr4-
dependent exocytotic process (5). UPEC organisms that subvert
this expulsion process can escape into the cytoplasm of bladder
epithelial cells, where they are protected from immune detection
(3) and replicate to high numbers, forming biofilm-like intracel-
lular bacterial communities (IBCs), in a process that is also depen-
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dent on type 1 pili (6, 7). IBCs have been extensively characterized
in murine models of UTIs and are found in the urine of UTI
patients (8). IBCs also correlate with UTI recurrence in children
(9). Because type 1 pili and FimHmediatemany of the initial steps
in UTI pathogenesis, UPEC strains lacking type 1 pili or the FimH
adhesin are significantly attenuated in murine cystitis models (7,
10, 11).
Given the importance of type 1 pili inUTI pathogenesis (7, 10),
their regulation and assembly have been studied in detail. The
fimS promoter for the fim operon is encoded on a 314-bp genomic
element that can be reoriented into the phase ON or OFF orien-
tation by site-specific recombinases that cleave at specific inverted
repeat sites flanking the fimS promoter, thus allowing or prevent-
ing fim expression (12, 13). Numerous regulators and environ-
mental signals have been shown to impact the fimS phase state and
thus type 1 pilus expression (14). One of these signals is the assem-
bly status of type 1 pili themselves. Fim subunits in the periplasm
require the FimC chaperone for proper folding. Each subunit has
an incomplete Ig-like fold and an amino-terminal extension.
FimC acts as a template for subunit folding by transiently donat-
ing a -strand to complete the subunit’s Ig fold, a process termed
donor strand complementation (15). Chaperone-subunit com-
plexes then interact with the outermembrane usher, FimD, which
catalyzes pilus assembly. In a process termed donor strand ex-
change, an incoming pilin subunit donates its amino-terminal
extension to complete the Ig-like fold of the previously incorpo-
rated pilin subunit. Donor strand exchange displaces the chaper-
one-strand and results in the noncovalent polymerization of the
pilin subunits (16–18). Disruption of this assembly process can be
sensed by the bacteriumand results in the down-regulation of type
1 pilus expression by biasing the invertible fimS promoter toward
the phase OFF orientation (19).
In humans, collection of tissue biopsy specimens during infec-
tion is generally contraindicated, so there has been significant in-
terest in profiling theUPEC physiological response to infection by
examining human urine. Of note, human urine is a complex bio-
fluid that contains over 2,000 metabolites (20), and a person’s
health, as well as his/her food and drug intake, impacts the pres-
ence and concentration of the metabolites in their urine. Further-
more, urine from healthy individuals can contain low levels of
erythrocytes, leukocytes, and sloughed epithelial cells from the
urinary tract. Therefore, while type 1 pili are essential for infection
and highly expressed in mice during UTI, their expression in hu-
man urine samples has been reported to be variable. One study
found by immunofluorescence that 75% of UPEC strains from
UTI patients were type 1 piliated (21). A study by Bielecki and
colleagues found that while 19/21 (90%) human urine samples
contained UPEC that expressed fimA, encoding the type 1 pilus
major subunit, only 8 (38%) of those samples had high levels of
fimA transcript (22). Hagan and colleagues used a CFT073-
specific microarray to measure gene expression from the urine of
eight women with E. coli bacteriuria and found that type 1 pilus
genes were detectable in two of the eight samples (23). A recent
study using RNA-Seq to quantify UPEC gene expression also
found variable fim expression in UTI samples (24). Of note, pili
that are assembled on the cell surface probably remain there for
several cell divisions, likely leading to differences in pilus tran-
script and piliation levels, as seen in the studies cited above. There
has also been extensive characterization of type 1 piliation in the
murine model of UTI. In one study, UPEC from the urine of
infected mice demonstrated variable fimS phase orientation, with
some infectedmice containingmostly phaseONUPECandothers
mostly phase OFF UPEC in their urine, reflective of the data from
human studies (25). In that study, the percentage of the UPEC
population in the fimS phase ON state increased over the first 24 h
of murine cystitis, and the fimS phase ON state positively corre-
lated with infection burden (25). Furthermore, when the urine
from mice, 24 h postinfection, was filtered through a 12-m-
pore-size filter, the UPEC organisms which were adherent to eu-
karyotic cells, and therefore retained on the filter, were enriched
for phase ON bacteria (with a mean of 49% phase ON) relative to
the planktonic UPEC organisms that passed through the filter,
which were mostly fimS phase OFF (25). Further, nonpiliated
UPEC organisms have been identified inmurine urine, evenwhen
those in the murine bladder are piliated (26).
Thus, type 1 pilus expression in urine appears to be variable
between different human patients and betweenmice and humans.
One hypothesis that integrates these seemingly disparate results is
that different external signals encountered during infection (i.e.,
different niches) impact type 1 pilus expression. Therefore, amore
complete understanding of the effect that temporal-spatial niches
within the urinary tract occupied by UPEC have on type 1 pilus
expression during UTI is required. Host responses to bacteria in-
clude micturition to wash away unattached bacteria, Tlr-4 depen-
dent exocytosis of invaded bacteria (5), and exfoliation of host
cells containing IBCs or that have extracellularly attached bacteria
(27). Thus, urine can contain UPEC (i) growing planktonically in
urine, (ii) adherent to bladder epithelial cells, or (iii) present in
biofilm-like communities inside exfoliated bladder urothelial
cells. These various niches may all affect the expression of type 1
pili and regulation of fimS phase orientation during infection.
To better understand the extracellular niches, we directly mea-
sured the impact of growth in urine on fimS phase state, type 1
piliation, and type 1 pilus function. We found that planktonic
growth in human urine turns UPEC fimS phase OFF, inhibiting
further type 1 pilus expression. However, bacteria adherent to
human bladder cells remain phase ON despite growth in human
urine. We also found that urine inhibits the function of the type 1
pilus adhesin, FimH, independent of expression. This functional
inhibition in turn further impacts fimS phase regulation. There-
fore, niche residence within the urinary tract impacts the expres-
sion of type 1 pili. More generally, depending on the level of
urothelial exfoliation and the impact of other spatial-temporal
factors, genes associated with tissue-specific expression may not
always correlate with the transcriptome of UPEC in the urine
niche.We propose that human urine exerts an inhibitory effect on
type 1 pilus expression and function, blockingUPEC colonization
and thus defending against the onset of UTI, similar to an innate
defense mechanism. Finally, the regulatory connection between
FimH function and fimS phase state could increase the efficacy of
therapeutics targeting FimH function.
RESULTS
Human urine impacts type 1 piliation and phase variation. We
used a hemagglutination assay (HA) to quantify the effects of
growth in urine on type 1 piliation on the UPEC cell surface. In an
HA, normalized bacteria are serially 2-fold diluted, and the titer
indicates the maximum dilution still capable of agglutinating
guinea pig erythrocytes. Mannose acts as a competitive inhibitor
of type 1 pilus-mediated adhesion, abolishing agglutination by
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type 1 pili. Using type 1 pilus-inducing conditions (two 24-h pe-
riods of static growth at 37°C), we found that growth of the pro-
totypical UPEC isolate UTI89 in filtered human urine compared
to growth in LB decreased HA titers from 28 to 22 (Fig. 1A). This
result indicates a decrease in type 1 piliation, inhibition of FimH
function, or both. To distinguish between these possibilities, we
used the highly piliated fimS phase-locked-ON UTI89 mutant,
which has point mutations incorporated into its left inverted re-
peat (LIR), such that the recombinases can no longer cleave and
reorient the fimS promoter element into the OFF orientation. The
HA titer of the fimS phase-locked-ON strain grown in LB showed
no change after a 1-h exposure to filtered human urine, indicating
that filtered humanurine does not contain a direct FimH inhibitor
(Fig. 1B). Thus, the decreased HA titer observed after growth in
filtered human urine likely reflects decreased type 1 piliation on
the UPEC cell surface.We confirmed this result with immunoblot
analysis, which showed that after growth in filtered human urine,
FimA, the type 1 pilus major subunit, was no longer detectable
(Fig. 1C). To further confirm the impact of growth in urine on
CUPpiliation, we quantified the extent of piliation on the surfaces
of individual UTI89 cells grown statically in LB or in filtered hu-
man urine twice for 24 h each time by electron microscopy (EM).
We found that growth in urine increased the proportion of non-
piliated and slightly piliated cells (Fig. 1D). The absence of any
detectable FimA in the immunoblot (Fig. 1C) suggests that at least
some of the pili observed by EM in Fig. 1D likely represented
non-type 1 CUP pili. Together, these assays demonstrate that,
relative to static growth in LB, static growth in filtered human
urine decreases the level of assembled type 1 pili on the cell surface,
which was reflected by a lack of FimA protein in whole-cell ex-
tracts.
To further examine the impact of growth in urine on type 1
pilus expression, we assessed the fimS phase state. Static growth
twice for 24 h each induces the fimS phase ON state in LB. To
determine how urine impacts the induction and maintenance of
fimS phase state, we prepared both ON and OFF initial inocula
and back-diluted them 1:1,000 for two 24-h periods of static
growth in LB or filtered human urine. Growth of a fimS phase ON
inoculum in filtered human urine resulted in the fimS phase OFF
state, while cells grown in LB remained phase ON (Fig. 2A). Al-
ternatively, growth of a fimS phase OFF inoculum in filtered hu-
man urinemaintained the fimS phase OFF state, while cells grown
in LB turned from phase OFF to phase ON (Fig. 2A). Quantifica-
tion of the fimS phase state indicated that growth in filtered hu-
man urine significantly impacts fimS phase orientation, favoring
the phase OFF state (Fig. 2B). We also confirmed that filtered
human urine induces the fimS phase OFF orientation and de-
creases type 1 piliation levels in another UPEC strain, CFT073,
and in the K-12 strain MG1655, indicating that this is not a
UTI89-specific phenotype (see Fig. S1 in the supplemental mate-
rial). These E. coli isolates also grew similarly to UTI89 in human
urine (see Fig. S1).
UPEC colonizing the bladder can be planktonic in urine or
attached to the luminal surface of the bladder epithelium. We
therefore assessed the impact of UPEC attachment to bladder ep-
ithelial cells on fimS phase state. UPEC attached to paraformalde-
hyde (PFA)-fixed 5637 bladder cells remained phase ON, even
after growth in human urine (Fig. 2C). Under these conditions,
phaseOFFUPECdid not convert to the phaseONorientation and
could not attach to the bladder cells. Thus, growth in filtered hu-
man urine both maintains and induces the fimS phase OFF state,
FIG 1 Effect of urine on type 1 piliation. (A) HA of UTI89 after growth under type 1 pilus-inducing conditions, in LB or filtered human urine. (B) HA of locked
ON strain LIR grown under type 1 pilus-inducing conditions in LB and then incubated in LB or filtered or unfiltered human urine for 1 h before HA was
conducted. The same batches of urine were used to compare filtered and unfiltered urine. (C) FimA immunoblot of UTI89 after growth under type 1
pilus-inducing conditions, in LB or filtered human urine. (D) Percentage of the population of each strain with abundant, moderate, low, or no piliation, as
assessed by counting 300 cells on electron micrographs.
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decreasing type 1 piliation level, an effect that was overcome by
attachment to bladder epithelial cells.
Impact of pH on type 1 pilus expression. Type 1 piliation re-
sponds to a variety of environmental signals. The filtered human
urine used in these experiments had pHvalues ranging from5.3 to
7, which is in the normal range of urine pHbut below the pHof LB
(7.4). We therefore investigated whether the lower pH was re-
sponsible for the urine effect on fimS phase state and type 1 pilia-
tion level. We investigated the fimS phase state after growth in LB
at different pHs. Growth in LB of pH 7, 6, or 5.5 had only a little or
no effect on the fimS phase state, compared to growth in LB at
pH 7.4 (Fig. 3A and B). The impact of low pH on the type 1
piliation level was quantified with HA titers of 28 after growth in
LB of pH 7.4 and 27 after growth in LB at pH 5.5 (Fig. 3C). To
differentiate between direct inhibition of pilus assembly versus
alteration of regulation, we also grew the fimS phase-locked-ON
(LIR) strain at lowpHand observed no effect on type 1 piliation or
function (Fig. 3D). Thus, the slight effect of pH on type 1 piliation
was probably through regulation of expression, but this effect does
not account for the ability of urine to induce the fimS phase OFF
orientation and significantly decrease type 1 piliation. Thus, urine
has a pH-independent mechanism for impacting fimS phase vari-
ation and type 1 piliation.
Whole urine inhibits FimH function. The experiments de-
scribed above were performed with pooled human urine that was
filtered to remove any bacteria or eukaryotic cells. However, fil-
FIG 2 Effect of urine on fimS phase state. UTI89 was grown under type 1 pilus-inducing conditions to produce a fimS phase ON inoculum or under fimS phase
OFF-inducing conditions to produce a phaseOFF inoculum. Each inoculumwas subcultured in LBor urine and grown twice for 24 h each time at 37°C. (A) Phase
assay demonstrates the percentage of the population in the fimS phase ON or OFF orientation after two 24-h periods of growth in the indicated medium from
a phase ON or phase OFF starting inoculum. (B) Graph of the ImageJ quantification of three biological replicates of the phase assay shown in panel A. (C) Phase
assay of the attached or planktonic population after two 24-h growth periods with PFA-fixed 5637 bladder cells. Asterisks indicate statistical significance, as
measured by the Mann-Whitney t test (P 0.05)
FIG 3 Impact of pH on fimS phase state and type 1 piliation. (A) Phase assay of UTI89 after two 24-h periods of static growth at 37°C in LB at the indicated pHs.
(B) Quantification of three biological replicates of the phase assay shown in panel A to quantify the percentage of the population in the fimS phase ON state. (C)
HA titers of UTI89 after two 24-h periods of static growth at 37°C in LB at the indicated pHs. (D)HA titers of the fimS phase-locked-ON strain LIR after two 24-h
periods of static growth at 37°C in LB at the indicated pHs. These experiments were conducted in triplicate.
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tration also removed some proteins (see Fig. S2 in the supplemen-
tal material). Urine can contain mannosylated proteins, such as
Tamm-Horsfall, as well as a variety of other types of proteins,
carbohydrates, and small molecules that can impact FimH func-
tion. For example, previous studies have found that urine contains
mannooligosaccharides and Tamm-Horsfall that can bind to type
1 pili and act as soluble inhibitors of FimH function (28). Consis-
tent with these reports, we demonstrated that a 1-h incubation of
piliated UTI89 (LIR) with unfiltered human urine decreased HA
titers, indicating inhibition of FimH function (Fig. 1B). The same
incubation of piliated cells with filtered urine had no impact on
FimH function, indicating that a FimH inhibitor(s) inwhole urine
was removed by filtration.
Genetic inactivation of FimH function impacts fimS phase
state but does not impede pilus assembly. To test whether abol-
ishing FimH function could result in further regulatory effects, we
examined the fimS phase state in the point mutant UTI89-fimH
Q133K, which contains a point mutation in the FimH mannose-
binding pocket that abrogates mannose binding. UTI89-fimH
Q133K switches to the fimS phase OFF state, even after growth
under type 1 pilus-inducing conditions (29). We found that the
phase defect in thismutant can be complemented by expression of
wild-type fimH in trans, indicating that there were no unintended
effects of this mutation on the other type 1 pilus components
(Fig. 4A). Thus, inactivation of FimH function biases fimS toward
the phase OFF state.
Type 1 pili are assembled by the chaperone-usher pathway, and
defects in pilus assembly are known to impact the fimS phase
switch. For example, strainswith deletions of fimC, the type 1 pilus
chaperone, switch to the fimS phase OFF state, even after growth
under type 1 pilus-inducing conditions (19). Furthermore, it was
demonstrated previously that the chaperone-adhesin complex
FimCH has the highest binding affinity for the FimD usher of any
chaperone-subunit complex and that FimCHbinding alters FimD
structure (30, 31). Thus, it is proposed that the binding of the
FimCH complex to the FimD usher initiates pilus assembly. To
assess whether the fimH Q133K mutation prevented or slowed
pilus assembly, we created a phase-locked-ON fimH Q133K mu-
tant, LIR-fimHQ133K.We also created a LIRfimH strain, which
encodes all the type 1 pilus components except the FimH adhesin,
under the control of thefimSphase-locked-ONpromoter. By elec-
tron microscopy, we quantified the percentage of cells with abun-
dant, moderate, low, and no piliation. The LIRfimH strain pro-
duced very few piliated cells, confirming that FimH is needed for
pilus assembly, as predicted based on the interactions of FimCH
and FimD (31) (Fig. 4B). However, the LIR and LIR-fimHQ133K
strains were similarly piliated, demonstrating that while the
Q133K mutation in fimH results in nonpiliated cells, it does not
cause a defect in pilus assembly (Fig. 4B). Thus, the fimH Q133K
functionally null mutant impacts fim phase state, but not through
defects in pilus assembly. This represents a novel form of type 1
pilus regulation.
Chemical inhibition of FimH affects type 1 pilus phase state.
Mannosides, small molecules derived from mannose, bind with
very high affinity in the FimH mannose-binding pocket (32, 33).
Growth in mannoside ZFH269 does not alter pilus assembly, as
measured by EMof the fimS phase-locked-ON strain (LIR) grown
in LB or LB with ZFH269 (Fig. 4B). However, growth with man-
noside ZFH269 (Fig. 4C) under type 1 pilus-inducing conditions
induced UTI89 cells to turn fimS phase OFF (Fig. 4D). Thus, both
a genetic inactivation of FimH function in the fimH Q133K mu-
tant and a chemical inhibition of FimH function with mannoside
resulted in fimS switching to the phase OFF state. In both cases,
type 1 pili are prevented from binding to a solid mannosylated
surface, which may explain the effect on fimS phase. Attachment
to a solid surface, such as PFA-fixed 5637 bladder epithelial cells,
FIG 4 FimH inhibition. (A) Phase assay of UTI89 and fimH:Q133K with or without FimH complementation in trans by pfimH, after growth under type 1
pilus-inducing conditions. (B) Percent of the population of each strainwith abundant,moderate, low, or nopiliation, as assessed by counting 300 cells on electron
micrographs. LIR is the fimS phase-locked-ONmutant. ZFH269 is the mannoside used. (C) Structure of mannoside ZFH269. (D) Phase assay of UTI89 grown
under type 1 pilus-inducing conditions with DMSO vehicle control or 25 M mannoside ZFH269.
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maintains the fimS phase ON state of UPEC even when these bac-
teria are grown in human urine (Fig. 2C). Possibly, physical ten-
sion on the pilus resulting from surface attachment inducesUPEC
to remain phase ON and continue expressing type 1 pili. Alterna-
tively, the genetic and chemical perturbationsmay act via separate
regulatory pathways that converge on the fimS promoter.
Recombinases control phase state in response to FimH inac-
tivation. To further investigate these regulatory pathways, we in-
vestigated the impact of fim recombinases on the fimS phase state
during chemical and genetic manipulation of FimH. Many envi-
ronmental conditions and regulators are known to impact fim
expression by controlling fimB and fimE recombinase expression
level or activity.While the fimHQ133K strain was 11% phase ON,
a fimHQ133KfimE strainwas 94%phaseONafter growthunder
type 1 pilus-inducing conditions (Fig. 5A and C). The fimH
Q133K and fimHQ133K fimB strains showed no significant dif-
ference in the percentage of fimS phase ON cells (Fig. 5C). There-
fore, FimE, but not FimB, appears to control phase status in re-
sponse to FimH functional inactivation.
We similarly found that UTI89 grown with mannoside
ZFH269 was more fimS phase OFF than UTI89fimE grown with
mannoside (Fig. 5B and D). Therefore, fimE is at least partially
required to turnUTI89 fimS phaseOFF in response to both chem-
ical and genetic FimH inactivation.
Overall, our experiments indicate that unfiltered human urine
possesses two different mechanisms for inactivating type 1 pili:
induction of the fimS phase OFF state and inactivation of FimH
function, which itself impacts phase state.
DISCUSSION
UPEC organisms encounter several niches during the course of
cystitis, including (i) urine, (ii) the luminal surface of the bladder
mucosa, and (iii) the intracellular cytoplasmic space of bladder
epithelial cells, where intracellular bacterial communities form.
Type 1 pili mediate binding and invasion of human bladder cells
(3, 4). They are necessary for the colonization and invasion of the
murine bladder and thus are critical for UTIs in mice (7, 10, 11).
Here, we investigated the effect of the urine niche on type 1 pilus
expression and function, showing a general reduction of type 1
piliation and inhibition of type 1 pilus function by urine.
Human urine acts via at least two independent mechanisms to
reduce type 1 pilus expression and function: (i) induction of the
fimS phase OFF orientation, through a mechanism independent
of both pH and direct FimH binding, thus preventing fim expres-
sion and further production of type 1 pili, and (ii) competitive
inhibition of FimH-mediated attachment, presumably bymanno-
sylated urine proteins, which in turn may further impact fimS
phase state. Despite the fact that competitive FimH inhibition
leads to the fimS phase OFF orientation, urine does mediate an
independent effect on the fimS phase orientation, as growth in
filtered urine, which does not inhibit FimH function, also induced
the fimS phase OFF state. The combination of these urine effects
leads to nearly complete loss of type 1 pilus expression (98% by
HA titer; 100% by FimAWestern blot analysis) during planktonic
growth in urine. On a shorter time scale (1 h), unfiltered urine
leads to a 50% reduction in FimH function, as measured by HA
titer (Fig. 1). This dual effect of urine on type 1 pilus expression
and function is especially important given that type 1 pili likely
remain on the cell surface long after fim transcription is turned off.
Thus, effectively inhibiting type 1 pilus-mediated attachment in-
cludes blocking both the function of pili on the cell surface and the
production of new pili. We also found that UTI89 grows very
poorly in filtered human urine, especially compared to growth in
a richmedium such as Luria broth (LB). UTI89 grew to 11% (95%
confidence interval [CI], 8.7 to 13.2) of the final bacterial culture
density compared to growth in LB. Altered growth rate or metab-
olism in urine may directly impact type 1 pilus expression. How-
ever, it is also possible that urine acts through other upstream
regulators that indirectly affect type 1 pilus expression. The com-
bined effect of inhibition of type 1 pilus-mediated binding and
physical expulsion by micturition represents a non-immune-cell-
mediated mechanism to defend against UTIs.
In this study, we found that planktonic growth in urine induces
the phase OFF orientation of the fimS promoter. Interestingly,
fimS phase OFF UPEC organisms have been found to rapidly
adopt the fimS phase ON orientation upon inoculation into the
murine bladder (34). In mouse models, UPEC organisms that
were adherent to sloughed bladder epithelial cells were more fimS
phase ON than unattached UPEC organisms (25). We have con-
firmed that UPEC organisms attached to bladder epithelial cells
remain phase ON, even during growth in human urine. Interest-
FIG 5 Role of fim recombinases in controlling phase state after FimH inhibition. (A) Phase assay of UTI89 and UTI89 isogenic mutants grown under type 1
pilus-inducing conditions. (B) Phase assay of UTI89 and UTI89fimE isogenic mutants grown under type 1 pilus-inducing conditions with DMSO or 25 M
mannoside ZFH269. (C andD) ImageJ quantification of the phase state in represented in panels A andB, respectively, by phase assay. Graphs showquantification
of three biological replicates.
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ingly, binding to epithelial cells leads to UPEC invasion; once in-
side a bladder epithelial cell, UPEC organisms are presumably
protected from traditional innate immune defenses and any in-
hibitory effects of urine. Thus, UPEC organisms in the urinary
tract experience competing signals, whichmay vary with time and
position, that are integrated at the fimS promoter to determine
production of type 1 pili and thus UPEC binding, persistence, and
infection. Similarly, it seems likely that expression of other viru-
lence factors are also affected by different signals present in these
different niches.
Previous characterization of type 1 pilus function, and the
structure of the FimH adhesin, has enabled the development of
mannosides, soluble mannose derivatives that bind with high af-
finity to FimH (32, 33). Mannosides block UPEC attachment to
and invasion of bladder epithelial cells and formation of intracel-
lular bacterial communities (IBCs), an important step in UPEC
pathogenesis. Furthermore, mannosides have been shown to suc-
cessfully prevent and/or to treatUTIs in amurinemodel, after oral
delivery (32). These effects have been attributed to mannoside
directly inhibiting FimH binding. We have now demonstrated
thatmannosides, like urine, also exert a regulatory effect by inhib-
iting phase variation into the fimS phase ON state. This is likely
similar to the mechanism by which genetic defects in the FimH
mannose-binding pocket, as in the FimH Q133K mutation, in-
duce the fimS phase OFF state. Thus, we propose that mannosides
may derive additional potency for treating UTIs from a combina-
tion of directly blocking FimH-mediated binding and invasion of
bladder tissue and induction of the fimS phaseOFF state, reducing
overall type 1 pilus expression. This is particularly interesting
given that both genetic and chemical inactivation of type 1 pilus
assembly (disrupting the donor strand exchange process in the
periplasm without direct effects on FimH adhesion) have also
been found to induce the fimS phase OFF state (19). In summary,
the fimS promoter is impacted by chemical and/or genetic inter-
ference with type 1 pilus function and assembly in order to switch
to the fimS phase OFF state. This intrinsic regulatory feedback
may prove beneficial in the development of therapeutics targeting
type 1 pili and other adhesive organelles.
Recent transcriptional profiling studies of UTIs have been per-
formedonbacteria from the urine of patientswithUTI (23, 24). In
those studies, UPECwas found to have variable expression of type
1 pili. This finding is consistent with previous work, which re-
vealed a dichotomy between piliated tissue-associated UPEC and
nonpiliated bacteria found in the urine of the same infectedmouse
(26). Furthermore, UPEC growth in urine is planktonic, while
attachment to and invasion of the bladder epithelium involves
biofilm-like communities. These nichesmay provide different nu-
trient availability, immune protection, or other benefits and chal-
lenges. Therefore, a complete understanding of UPEC virulence
necessitates consideration of UPEC biology within these different
niches over time. The transcriptomes of urine- and tissue-
associated UPEC are thus likely to contain important differences,
for example in type 1 pilus expression, in part depending on the
level of exfoliated epithelial cells in the urine at the time of collec-
tion. Understanding these spatial-temporal complexities will pro-
vide insight into additional ways the host impacts UPEC physiol-
ogy and virulence. Further, antivirulence compounds targeting
FimHmay supplement urine’s effects to block FimH function and
fim expression, increasing their therapeutic potential.
MATERIALS AND METHODS
Bacterial growth conditions. Experiments were conducted on the proto-
typical UPEC strain UTI89 or the isogenic UTI89 mutants listed in Ta-
ble 1. Phase ON-inducing conditions (type 1 pilus-inducing conditions)
were static incubation at 37°C for 24 h and then subculturing 1:1,000 for
an additional 24-h static incubation at 37°C (30). Phase OFF-inducing
conditions were shaking incubation at 25°C for 24 h and then subcultur-
ing 1:1,000 for an additional 24 h with shaking incubation at 25°C. Type 1
pilus-inducing (phase ON) and phase OFF-inducing conditions utilized
growth in Luria broth (LB), unless otherwise stated. Growth was always
twice for 24 h each, unless otherwise specified. Urine was collected from
healthy human volunteers according to institutional review board (IRB)
protocol (201207143) and filtered through a 0.22-m filter before use,
unless otherwise specified. Urine was pooled from at least two healthy
volunteers for each experiment. M9 minimal medium contained 0.2%
glucose as the sole carbon source and 10 g/ml niacin.
Mannoside. Mannoside ZFH269 was made as previously described
(32).
Phase assay. To quantify the percentage of a bacterial population in
each phase state, the fimS promoter region of UTI89 and UTI89 isogenic
mutants was PCR amplified out of whole bacterial cells, and then the PCR
product was digested with the restriction enzyme Hinf1 at 37°C for 2 h.
The resultingDNAproducts were resolved on a 2% agarose gel (12). DNA
band intensity was quantified by ImageJ. The percent phase ON was cal-
culated as 100 (intensity of the top phase ON band/intensity of the top
phase ON and OFF bands).
Tissue culture. 5637 bladder epithelial cells (ATCC HTB-9) were
seeded into 6-well tissue culture plates and grown to confluence in RPMI
1604 medium with 10% fetal bovine serum. The cells were washed three
times with phosphate-buffered saline (PBS) and fixed with 4% parafor-
maldehyde (PFA) for 1 h. Fixed cells were washed three times with PBS
prior to inoculation with phase ON or OFFUTI89 culture diluted 1:1,000
into 3 ml pooled and filtered human urine. After two 24-h periods of
TABLE 1 Bacterial strains and plasmids
Strain or plasmid Description Reference or source
Strains
UTI89 UPEC strain isolated from the urine of a patient with cystitis 36
MG1655 K-12 laboratory strain 37
CFT073 UPEC strain isolated from the blood of a patient with pyelonephritis 38
UTI89-fimH:Q133K Q133K point mutation in fimH, Kmr 29
UTI89fimH UTI89fimH 7
LIR Mutation of the fimS left inverted repeat 39
LIR-fimH:Q133K Mutation of the fimS left inverted repeat, Q133K point mutation in fimH, Kmr This study
LIRfimH Mutation of the fimS left inverted repeat, fimH This study
Plasmid
pfimH pBAD33-fimH This study
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growth at 37°C, culture supernatant was removed and used as the plank-
tonic fraction for phase assays. Bladder andUTI89 cells were washed three
times with PBS, scraped off the bottoms of the wells, and used as the
attached fraction for phase assays.
HA. Bacteria were grown under type 1 pilus-inducing conditions. Pi-
lus expression was assessed by hemagglutination assays (HA) as previ-
ously described (35) using bacterial cultures normalized to an optical
density at 600 nm (OD600) of 1 and guinea pig erythrocytes normalized to
an OD640 of 2. The experiment was conducted in parallel with PBS–4%
mannose.
Electron microscopy. Electron micrographs were taken of UTI89 or
UTI89 isogenic mutants after growth under type 1 pilus-inducing condi-
tions, with or without 25 M mannoside ZFH269 or dimethyl sulfoxide
(DMSO) vehicle control. A total of 300 bacterial cells were counted for
each condition, and piliation on those cells was classified as bald (no pili),
low (1 to 20 pili/cell), moderate (20 to 200 pili/cell), or abundant (200
pili/cell).
Bacterial culture density. Final culture density was measured by ab-
sorbance at 600 nm.
Immunoblot analyses. UTI89 and the LIR isogenic mutant were
grown under type 1 pilus-inducing conditions in LB or filtered human
urine. Cells were briefly agitated to mix the entire culture prior to sample
collection by centrifugation, normalization to an OD600 of 10, and anal-
ysis by SDS-PAGE. Membranes were probed with antisera for FimA at
1:10,000.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org/
lookup/suppl/doi:10.1128/mBio.00820-15/-/DCSupplemental.
Figure S1, JPG file, 0.7 MB.
Figure S2, JPG file, 0.7 MB.
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